New Device Could Keep Weight Off After GLP-1 Drugs
Elie Dolgin, IEEE Spectrum Christina had tried dieting and exercise before. The weight always came off but then crept back on, especially after she gave…
Our 5 predictions for dating in 2026
New year, new love? Maybe not, according to Mashable’s dating predictions for 2026. With 2026 within kissing distance, many of us will be mulling over our resolutions for the year ahead. Will I fall in love this year? Will dating continue to be a dumpster fire? Will we enter a post-dating era? Will we all be […]
How Do GLP-1 Shots Help With Weight Loss?
GLP-1 shots are a hot topic among the beauty and wellness community, often described as celebrities’ best-kept secret behind their miraculous weight loss. The… The post How Do GLP-1 Shots Help With Weight Loss? appeared first on The Art of Healthy Living.
Where is Novo Nordisk A/S (NVO) Headed?
Novo Nordisk A/S (NYSE:NVO) is one of the best affordable healthcare stocks to buy now. On December 22, Novo Nordisk A/S (NYSE:NVO) announced the FDA approval of the Wegovy® pill, a once-daily oral semaglutide 25 mg, for long term weight management, excess body weight reduction, and reduction in the risk of major adverse cardiovascular events. The approval makes […]
WEIGHTLESS
The author’s ethos throughout her discussion of GLP-1 medications is that obesity is a chronic issue that doctors treated from the wrong perspective: “For too long, we approached chronic conditions such as obesity as ‘willpower problems’ or moral failings….We treated the symptoms but did nothing to treat the disease because we didn’t fully understand it […]
Jim Cramer Discusses Molson Coors (TAP) & Alcohol Industry
We recently published 8 Stocks on Jim Cramer’s Radar. Molson Coors Beverage Company (NYSE:TAP) is one of the stocks on Jim Cramer’s radar. Molson Coors Beverage Company (NYSE:TAP) is an alcoholic beverage company. The shares are down by 18% year-to-date as the firm has struggled due to the broader weakness in the alcoholic beverage industry. […]
Jim Cramer Discusses Brown-Forman (BF-B) & Alcohol Industry
We recently published 8 Stocks on Jim Cramer’s Radar. Brown-Forman Corporation (NYSE:BF-B) is one of the stocks on Jim Cramer’s radar. Brown-Forman Corporation (NYSE:BF-B) is another alcoholic beverage firm whose shares have struggled in 2025. The stock is down by 29% year-to-date and has suffered particularly in 2025. Since December 11th, Brown-Forman Corporation (NYSE:BF-B)’s shares […]
Lupin signs exclusive licensing deal with Gan & Lee for novel GLP-1 receptor agonist
Lupin announced that it has entered into an exclusive license, supply, and distribution agreement with China-based Gan & Lee Pharmaceuticals for Bofanglutide, a novel fortnightly GLP-1 receptor agonist.
Nutrients, Vol. 18, Pages 119: Intermittent Fasting and Probiotics for Gut Microbiota Modulation in Type 2 Diabetes Mellitus: A Narrative Review
Nutrients, Vol. 18, Pages 119: Intermittent Fasting and Probiotics for Gut Microbiota Modulation in Type 2 Diabetes Mellitus: A Narrative Review Nutrients doi: 10.3390/nu18010119 Authors: Zhiwen Zhang Shaokang Wang Guiju Sun Da Pan Background: Type 2 diabetes mellitus (T2DM) is a global epidemic in which gut microbiota dysbiosis contributes to impaired glucose homeostasis and chronic […]
Lupin shares in focus after licensing pact with China’s Gan & Lee for GLP-1 drug
Lupin Ltd has secured exclusive rights in India for Bofanglutide, a novel fortnightly GLP-1 receptor agonist, through a licensing agreement with China’s Gan & Lee Pharmaceuticals. This strategic move bolsters Lupin’s diabetes and obesity treatment portfolio, offering a convenient and effective option for patients amidst a growing metabolic health challenge in India.